1610-GMP, 4037809

Bachem Regulatory Documentation



α-Methyldopahydrazine; (S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid · H2O;
(S)-α-Hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid monohydrate;
(-)-L-α-Hydrazino-3,4-dihydroxy-α-methylhydrocinnamic acid monohydrate

Fields of Application

Parkinson’s disease

Active Substance

Carbidopa is a peripheral dopa-decarboxylase inhibitor which exhibits a distinct pharmacological activity only when given in combination with levodopa. Carbidopa inhibits the peripheral decarboxylation of levodopa to dopamine. As, unlike levodopa, carbidopa does not cross the blood-brain barrier, effective brain concentrations of dopamine are produced with lower doses of levodopa.

In the treatment of parkinsonism carbidopa is administered in combination with levodopa to allow a lower dosage of the latter, a more rapid onset of a response, and a mitigation of adverse effects.

Molecular Information

Molecular Formula

C10H14N2O4 · H2O

Relative Molecular Mass

226.23 g/mol (net) 244.25 g/mol (monohydrate)


28860-95-9 (net), 38821-49-7 (monohydrate)

Long-term Storage

Room temperature

Contact US